Harvest Fund Management Co. Ltd Takes $62,000 Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Harvest Fund Management Co. Ltd acquired a new position in ADMA Biologics, Inc. (NASDAQ:ADMA) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 3,112 shares of the biotechnology company’s stock, valued at approximately $62,000.

A number of other large investors have also modified their holdings of ADMA. Assenagon Asset Management S.A. grew its position in ADMA Biologics by 2.7% in the 3rd quarter. Assenagon Asset Management S.A. now owns 3,474,455 shares of the biotechnology company’s stock worth $69,454,000 after purchasing an additional 92,281 shares during the last quarter. Seven Eight Capital LP acquired a new position in ADMA Biologics during the 2nd quarter worth $1,992,000. Principal Financial Group Inc. grew its stake in shares of ADMA Biologics by 785.7% in the third quarter. Principal Financial Group Inc. now owns 1,194,221 shares of the biotechnology company’s stock worth $23,872,000 after purchasing an additional 1,059,394 shares in the last quarter. Louisiana State Employees Retirement System acquired a new position in shares of ADMA Biologics during the third quarter valued at $2,253,000. Finally, Point72 Asset Management L.P. bought a new stake in shares of ADMA Biologics during the second quarter valued at about $1,157,000. Institutional investors and hedge funds own 75.68% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on ADMA. Cantor Fitzgerald reiterated an “overweight” rating and issued a $20.00 target price on shares of ADMA Biologics in a research report on Friday, September 20th. HC Wainwright increased their price objective on shares of ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a report on Friday, November 8th. Finally, Raymond James raised their price objective on shares of ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a research note on Friday, November 8th.

ADMA Biologics Price Performance

NASDAQ:ADMA opened at $21.83 on Thursday. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. The business’s 50-day moving average price is $19.03 and its 200 day moving average price is $15.19. ADMA Biologics, Inc. has a 52-week low of $3.60 and a 52-week high of $23.64. The firm has a market cap of $5.16 billion, a P/E ratio of 77.96 and a beta of 0.64.

ADMA Biologics (NASDAQ:ADMA) last released its earnings results on Thursday, November 7th. The biotechnology company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.13 by $0.02. The business had revenue of $119.84 million during the quarter, compared to analyst estimates of $107.25 million. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. During the same period in the prior year, the business earned $0.01 earnings per share. As a group, sell-side analysts predict that ADMA Biologics, Inc. will post 0.52 earnings per share for the current fiscal year.

Insider Transactions at ADMA Biologics

In other ADMA Biologics news, COO Kaitlin M. Kestenberg-Messina sold 24,150 shares of the firm’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $16.90, for a total value of $408,135.00. Following the completion of the transaction, the chief operating officer now directly owns 449,088 shares in the company, valued at $7,589,587.20. This trade represents a 5.10 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Lawrence P. Guiheen sold 9,000 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $18.47, for a total transaction of $166,230.00. Following the sale, the director now owns 153,941 shares in the company, valued at $2,843,290.27. This represents a 5.52 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 48,150 shares of company stock valued at $891,615 in the last three months. 3.70% of the stock is currently owned by corporate insiders.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.